### 2025-08-29 Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium
- **Metadata:**
    - **Authors:** Otavio Cabral-Marques, Lena F. Schimke, Guido Moll, Igor Salerno Filgueiras, Adriel Leal Nóbile, Anny Silva Adri, Fernando Yuri Nery do Vale, Júlia Nakanishi Usuda, Yohan Lucas Gonçalves Corrêa, Débora Albuquerque, Roseane Galdioli Nava, Ronaldy Santana Santos, Haroldo Dutra Dias, Hélio Fernandes Silva, Pedro Batista Marconi, Rusan Catar, Michael Adu-Gyamfi, Pinchao Wang, Taj Ali Khan, Alexander M. Hackel, Anja Leheis, Anja Stähle, Antje Müller, Carolin Schmidt, Chiara Radunovic, El-Baraa Adjailia, Hanna Grasshoff, Jens Y. Humrich, Jonas Menz, Konstantinos Fourlakis, Maike Winziers, Maj Jäpel, Manuel Vincent Wegner, Peter Lamprecht, Relana Nieberding, Reza Akbarzadeh, Sabrina Arnold, Sebastian Jendrek, Sebastian Klapa, Solveig Augustin, Sophie Biedermann, Susanne Schinke, Patrick Scheererm, Matthias Endres, Kai Schulze-Forster, Friedemann Paul, Xinhua Yu, Franziska Sotzny, Thomas P. Sakmar, Miroslaw Banasik, Aiden Haghikia, Markus H. Hoffmann, Dmitry Veprintsev, Torsten Witte, Rodrigo J.S. Dalmolina, Hans D. Ochs, Harald Heidecke, Carmen Scheibenbogen, Gabriela Riemekasten, Yehuda Shoenfeld.
    - **Institutes:** University of São Paulo, Brazil; Universal Scientific Education and Research Network (USERN), Sao Paulo, Brazil; D'Or Institute for Research and Education, Rio de Janeiro, Brazil; Charité Universitätsmedizin Berlin, Germany; Khyber Medical University, Peshawar, Pakistan; University of Lübeck, Lübeck, Germany; The Rockefeller University, New York, NY, USA; Wroclaw Medical University, Wroclaw, Poland; Hannover Medical School, Hannover, Germany; University of Nottingham, Nottingham, United Kingdom; 27 Biotech Ltd., Nottingham, United Kingdom; Federal University of Rio Grande do Norte, Brazil; University of Washington School of Medicine, and Seattle Children's Research Institute, Seattle, WA, USA; Reichman University, Herzelia, Israel; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
    - **Publisher:** Autoimmunity Reviews
    - **Link:** [DOI](https://doi.org/10.1016/j.autrev.2025.103855)
- **What was researched?**
This paper summarizes the key insights and advancements presented at the 5th International Symposium on Regulatory Autoantibodies Targeting G-protein-coupled receptors (RAB-GPCRs). It explores the active role of these autoantibodies in various human diseases, including ME/CFS and post-COVID syndrome (PCS), and discusses their potential as diagnostic biomarkers and therapeutic targets.
- **Why was it researched?**
This report was compiled to consolidate the growing body of evidence that RAB-GPCRs, once considered passive markers, are in fact active modulators of cellular signaling, immune regulation, and inflammation. The symposium aimed to foster interdisciplinary collaboration and highlight this paradigm shift, discussing the involvement of these autoantibodies in a wide range of pathologies, from autoimmune diseases to post-viral syndromes.
- **How was it researched?**
This article is a comprehensive review and report of a scientific symposium. It synthesizes the presentations and discussions of leading experts from rheumatology, immunology, and neurology. The report draws upon numerous cited studies to construct a cohesive overview of the current understanding and future directions in RAB-GPCR research.
- **What has been found?**
The report highlights that autoantibodies targeting GPCRs are significantly involved in ME/CFS and PCS. One major finding discussed is that Epstein-Barr Virus (EBV) reactivation may be a key trigger, as certain EBV proteins contain sequences that mimic human GPCRs (molecular mimicry), leading to the production of cross-reactive autoantibodies. These autoantibodies, particularly those targeting adrenergic receptors, are associated with symptom severity in ME/CFS/PCS and are thought to contribute directly to symptoms like dysautonomia, fatigue, and cognitive dysfunction.
- **Discussion:**
The authors emphasize the major shift in understanding these autoantibodies, from being viewed as simple disease markers to being recognized as dynamic, functionally active agents. They discuss that these molecules can have both regulatory roles in health and pathogenic roles in disease, depending on factors like their concentration and specificity. This complexity challenges traditional immunological frameworks and calls for new conceptual models.
- **Conclusion & Future Work:**
The authors conclude that functional autoantibodies targeting GPCRs are central players in the mechanisms of many immune-mediated and post-viral diseases. They strongly advocate for future research to adopt integrative, systems-level approaches that combine autoantibody profiling with other biological data (multi-omics). Such work is expected to uncover shared disease mechanisms and accelerate the development of precision diagnostics and immunomodulatory therapies.
- **Summary:**
This symposium report is highly significant for ME/CFS patients as it strongly reinforces the autoimmune nature of the illness, centering on specific autoantibodies that disrupt critical cell receptors (GPCRs) responsible for regulating functions like blood pressure and immune response. It provides a plausible mechanism for how the illness can be triggered by a common infection, suggesting that Epstein-Barr Virus (EBV) reactivation can lead to these harmful autoantibodies through "molecular mimicry." By identifying these autoantibodies as active drivers of pathology, this research validates the biological basis of ME/CFS symptoms and paves the way for developing objective diagnostic tests and targeted treatments, such as therapies to remove or neutralize these antibodies.
- **Simple Summary:**
Scientists summarized new research showing that in ME/CFS, the immune system can create harmful antibodies that interfere with important cell functions. They presented evidence that the Epstein-Barr virus might trigger this process, which helps explain how an infection can lead to chronic illness. This work strengthens the understanding of the disease's biology and points toward new ways to diagnose and treat it.